You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma

  • Technology appraisal guidance
  • Reference number: TA226
  • Published:  22 June 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Lymphoma (follicular non-Hodgkin's ) - rituximab: consultee and commentator comments on the ACD

  • Lymphoma (follicular non-Hodgkin's ) - rituximab: Roche

  • Lymphoma (follicular non-Hodgkin's ) - rituximab: Lymphoma Association, Leukaemia CARE and Leukaemia & Lymphoma Research

  • Lymphoma (follicular non-Hodgkin's ) - rituximab: National Cancer Research Institute, Royal College of Physicians, Royal College of Radiologists, Association of Clinical Pathologists and Joint Collegiate Council for Oncology

  • Lymphoma (follicular non-Hodgkin's ) - rituximab: Royal College of Nursing

  • Lymphoma (follicular non-Hodgkin's ) - rituximab: Royal College of Pathologists and the British Society for Haematology

  • Lymphoma (follicular non-Hodgkin's ) - rituximab: Department of Health


No last updated information available

Back to top